Prospective Grant of Start-Up Exclusive Commercialization License: Anti-Tyrosine Kinase-Like Orphan Receptor 1 Immunotoxins for the Treatment of Human Cancers

Riepilogo

This is notice, in accordance with 35 U.S.C. 209 and 37 CFR part 404, that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of a start-up exclusive commercialization license to practice the inventions embodied in U.S. Patent Application 61/172,099 entitled "Anti-human ROR1 Antibodies" [HHS Ref. E-097-2009/0-US-01], U.S. Patent Application No. 13/990,977 entitled, "Chimeric Rabbit/Human ROR1 Antibodies" filed June 7, 2013 [HHS Ref. No. E-039-2011/0], U.S. Patent Application 60/703,798 entitled "Mutated Pseudomonas Exotoxins with Reduced Antigenicity" [HHS Ref. E-262-2005/0-US-01], U.S. Patent Application 60/969,929 entitled "Deletions in Domain II of Pseudomonas Exotoxin A that Remove Immunogenic Epitopes with Affecting Cytotoxic Activity" [HHS Ref. E- 292-2007/0-US-01], U.S. Patent Application 61/241,620 entitled "Improved Pseudomonas Exotoxin A with Reduced Immunogenicity" [HHS Ref. E-269-2009/0-US-01], U.S. Patent Application 61/483,531 entitled "Recombinant Immunotoxin Targeting Mesothelin" [HHS Ref. E-117-2011/ 0-US-01], U.S. Patent Application 61/495,085 entitled "Pseudomonas Exotoxin A with Less Immunogenic T-Cell/or B-Cel